Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 13/2017

01-12-2017 | Original Article

Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET

Authors: Jochen Hammes, Isabel Leuwer, Gérard N. Bischof, Alexander Drzezga, Thilo van Eimeren

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 13/2017

Login to get access

Abstract

Purpose

Cerebral glucose metabolism measured with [18F]-FDG PET is a well established marker of neuronal dysfunction in neurodegeneration. The tau-protein tracer [18F]-AV-1451 PET is currently under evaluation and shows promising results. Here, we assess the feasibility of early perfusion imaging with AV-1451 as a substite for FDG PET in assessing neuronal injury.

Methods

Twenty patients with suspected neurodegeneration underwent FDG and early phase AV-1451 PET imaging. Ten one-minute timeframes were acquired after application of 200 MBq AV-1451. FDG images were acquired on a different date according to clinical protocol. Early AV-1451 timeframes were coregistered to individual FDG-scans and spatially normalized. Voxel-wise intermodal correlations were calculated on within-subject level for every possible time window. The window with highest pooled correlation was considered optimal. Z-transformed deviation maps (ZMs) were created from both FDG and early AV-1451 images, comparing against FDG images of healthy controls.

Results

Regional patterns and extent of perfusion deficits were highly comparable to metabolic deficits. Best results were observed in a time window from 60 to 360 s (r = 0.86). Correlation strength ranged from r = 0.96 (subcortical gray matter) to 0.83 (frontal lobe) in regional analysis. ZMs of early AV-1451 and FDG images were highly similar.

Conclusion

Perfusion imaging with AV-1451 is a valid biomarker for assessment of neuronal dysfunction in neurodegenerative diseases. Radiation exposure and complexity of the diagnostic workup could be reduced significantly by routine acquisition of early AV-1451 images, sparing additional FDG PET.
Literature
1.
Bischof GN, Jessen F, Fliessbach K, et al. Impact of tau and amyloid burden on glucose metabolism in Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3:934–9.CrossRefPubMedPubMedCentral
2.
Dronse J, Fliessbach K, Bischof GN, et al. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer’s Disease. J Alzheimers Dis. 2016:1–7.
3.
Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.CrossRefPubMed
4.
Spina S, Schonhaut DR, Boeve BF, et al. Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology. 2017;88:758–66.CrossRefPubMed
5.
Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2016;43:1139–50.CrossRefPubMed
6.
Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord. 2017;32:170–1.CrossRefPubMed
7.
Cho H, Choi JY, Hwang MS, et al. Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017;32:134–40.CrossRefPubMed
8.
Whitwell JL, Lowe VJ, Tosakulwong N, et al. [18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017;32:124–33.CrossRefPubMed
9.
Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of (18) F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord. 2017;32:108–14.CrossRefPubMed
10.
Betthauser T, Lao PJ, Murali D, et al. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317. J Nucl Med. 2017;58:996–1002.CrossRefPubMed
11.
Xia C-F, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9:666–76.CrossRefPubMed
12.
Walji AM, Hostetler ED, Selnick H, et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59:4778–89.CrossRefPubMed
13.
14.
15.
16.
Teipel S, Drzezga A, Grothe MJ, et al. Multimodal imaging in Alzheimer’s disease: validity and usefulness for early detection. Lancet Neurol. 2015;14:1037–53.CrossRefPubMed
17.
Heiss WD, Herholz K, Pawlik G, et al. Positron emission tomography as a quantitative imaging method for demonstrating regional brain metabolism. Digitale Bilddiagn. 1984;4:37–45.PubMed
18.
Phillips AA, Chan FH, Zheng MMZ, et al. Neurovascular coupling in humans: Physiology, methodological advances and clinical implications. J Cereb Blood Flow Metab. 2016;36:647–64.CrossRefPubMed
19.
Mielke R, Pietrzyk U, Jacobs A, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med. 1994;21:1052–60.CrossRefPubMed
20.
Tiepolt S, Hesse S, Patt M, et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2016;43:1700–9.CrossRefPubMed
21.
Rostomian AH, Madison C, Rabinovici GD, et al. Early 11C-PIB frames and 18F-FDG PET measures are comparable: A study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173–9.PubMedPubMedCentral
22.
Meyer PT, Hellwig S, Amtage F, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393–400.CrossRefPubMed
23.
Lin K-J, Hsiao I-T, Hsu J-L, et al. Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2016;43:1304–14.CrossRefPubMed
24.
Hsiao I-T, Huang C-C, Hsieh C-J, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.CrossRefPubMed
25.
Jin S, Oh M, Oh SJ, et al. Additional value of early-phase 18F-FP-CIT PET image for differential diagnosis of atypical parkinsonism. Clin Nucl Med. 2017;42:e80–7.CrossRefPubMed
26.
Verfaillie SCJ, Adriaanse SM, Binnewijzend MAA, et al. Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? Eur Radiol. 2015;25:3050–9.CrossRefPubMedPubMedCentral
27.
Rodriguez-Vieitez E, Leuzy A, Chiotis K, et al. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow Metab. 2016; 0271678X16645593
28.
Evans AC, Collins DL, Mills SR, et al. 3D statistical neuroanatomical models from 305 MRI volumes. In: Nuclear Science Symposium and Medical Imaging Conference, 1993., 1993 I.E. Conference Record. 1993, pp. 1813–1817 vol.3.
29.
Fisher RA. Frequency distribution of the values of the correlation coefficient in samples from an indefinitely large population. Biometrika. 1915;10:507–21.
30.
Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224–47.CrossRefPubMed
31.
Makris N, Goldstein JM, Kennedy D, et al. Decreased volume of left and total anterior insular lobule in schizophrenia. Schizophr Res. 2006;83:155–71.CrossRefPubMed
32.
Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage. 2002;15:273–89.CrossRefPubMed
33.
Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of Fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.PubMed
34.
Vollmar S, Čížek J, Sué M, et al. VINCI-volume imaging in neurological research, co-registration and ROIs included. In: Kremer K, Macho V, editors. Forschung und wissenschaftliches Rechnen 2003. Göttingen: GWDG; 2004. p. 115–31.
35.
Wong CO, Thie J, Gaskill M, et al. A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging. BMC Nucl Med. 2006;6:4.CrossRefPubMedPubMedCentral
36.
Ossenkoppele R, Schonhaut DR, Schöll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67.CrossRefPubMedPubMedCentral
37.
Schonhaut DR, Ossenkoppele R, Bejanin A, et al. Tau-pet patterns overlap and exceed hypometabolism in Alzheimer’s disease. Alzheimers Dement. 2016;12:545–P547.CrossRef
Metadata
Title
Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET
Authors
Jochen Hammes
Isabel Leuwer
Gérard N. Bischof
Alexander Drzezga
Thilo van Eimeren
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 13/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3840-z

Other articles of this Issue 13/2017

European Journal of Nuclear Medicine and Molecular Imaging 13/2017 Go to the issue

Original Article

Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease

Original Article

Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results

Editorial

Saving costs in cancer patient management through molecular imaging

Original Article

Diagnostic accuracy of an artificial neural network compared with statistical quantitation of myocardial perfusion images: a Japanese multicenter study

Original Article

A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery

Original Article

TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma